NeuroBo Pharmaceuticals Inc
0.3732 - 5.63
Join Discuss about NRBO with like-minded investors
1/4/2022 [9:04 AM] GNPX- will ssr around low 3s so watching pops to 3.50-3.80 for a trade back to 3 or below [9:04 AM] PSTV- ideally gets loco and we see 2.50-3+ im not interested til those levels [9:05 AM] RELI- watching retest if 7.50-8.50 for short back sub 7 i will ignore if it drops sub 7 [9:05 AM] IMMX- no interest [9:06 AM] NRBO- reshort using 2.30-2.50 retest [9:09 AM] ISPC- possible short using 10.50-11.50 res gauge for a scalp
96 Replies 9 👍 12 🔥
Next Dividend Date
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of 4 drug candidates. The company's recently acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19 (patients not requiring ventilators). Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and a well-understood safety profile in humans. ANA001 is currently being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the U.S. Niclosamide has demonstrated both antiviral and immunomodulatory activity with possible downstream effects on coagulation abnormalities observed in COVID-19. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. Due to global COVID-19 crisis, a planned Phase 3 study was postponed. In the interim, NeuroBo is exploring a potential orphan drug indication targeting chronic pain for NB-01. NeuroBo's NB-02 drug candidate is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. The company's fourth program, Gemcabene, was developed for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease.